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T uberculosis (TB) remains a leading cause of morbidity and mortality in developing countries, claiming over a million lives annually (1) . Treatment of TB requires long and intensive combination drug therapy, which can be complicated by the presence of concurrent diseases. The noncommunicable disease diabetes mellitus (DM) impacts TB with increasing magnitude (2, 3) . At the moment, an estimated 15% of TB cases can be attributed to DM (3) .
Patients with DM have three times the risk of developing active TB compared to nondiabetics (3, 4) , probably because of impaired host defenses. In addition, patients with TB and DM show a worse response to TB treatment than patients with TB alone and thus face a higher risk of TB treatment failure, relapse after cure, and death (5) . The impact of DM will only increase further due to the rising prevalence of DM, especially in countries where TB is endemic. On the other hand, DM management is hampered by TB treatment. The TB drug rifampin possibly affects blood glucose itself and induces hyperglycemia by augmenting intestinal absorption of glucose or reducing insulin sensitivity (6, 7) .
Metformin is the first-choice antihyperglycemic drug to treat diabetes mellitus type 2. It is affordable and may be advantageous when combined with rifampin, as it is not metabolized. Metformin lowers both basal and postprandial plasma glucose (8) by inhibiting the production of hepatic glucose, reducing intestinal glucose absorption, and improving glucose uptake and utilization (9) . Interestingly, recent data show that metformin also inhibits the intracellular growth of M. tuberculosis, restricts disease immunopathology, and augments the efficacy of conventional TB drugs. It has even been suggested as a possible adjunctive to standard TB treatment in nondiabetic TB patients (10) .
Metformin is eliminated unchanged into the urine with a halflife of approximately 5 h (11) . Over a range of renal functions, the mean renal clearance in the population is approximately 4 times greater than that of creatinine, indicating that tubular secretion is the most important route of elimination (11) . The oral absorption, hepatic uptake, and renal excretion of metformin are largely mediated by membrane transporters of the solute carrier (SLC) family, namely, organic cation transporters 1, 2, and 3 (OCT1, OCT2, and OCT3) and multidrug and toxin extrusion proteins 1 and 2K (MATE1 and MATE2K) ( Fig. 1) (11, 12) . Genetic polymorphisms in these transporter genes explain at least some of the variability observed in metformin pharmacokinetics and drug responses (11) . Furthermore, from studies of humans and mice, we know that inhibitors of OCTs and MATEs can alter the disposition of concomitantly administered organic cations, increasing drug concentrations in the systemic or intracellular compartment depending on the preferential inhibition of OCTs or MATEs ( Fig.  1 ) (13) (14) (15) .
There is scant evidence on the degree to which metformin and TB drugs can be administered simultaneously without any anticipated drug-drug interactions (DDIs) and corresponding dose adjustments to retain optimal TB and DM treatment. Because metformin is not metabolized in the body and its disposition is largely dependent on OCTs and MATEs, any expected DDIs would be mediated primarily via these membrane transporters (Fig. 1) . Accordingly, this study sought to assess the in vitro inhibitory effects of TB drugs (rifampin, isoniazid, pyrazinamide, ethambutol, amikacin, moxifloxacin, and linezolid) on transport of metformin by OCT1, OCT2, OCT3, MATE1, and MATE2K. Furthermore, we investigated whether the tested TB drugs are substrates of OCT1, OCT2, OCT3, MATE1, and MATE2K and therefore can become a victim themselves of transporter-mediated DDIs.
MATERIALS AND METHODS

Chemicals and materials.
The following drugs were purchased from Sigma-Aldrich (Zwijndrecht, the Netherlands): rifampin, isoniazid, pyrazinamide, ethambutol dihydrochloride, amikacin, moxifloxacin hydrochloride, linezolid, and metformin hydrochloride. [ 14 C]metformin hydrochloride was obtained from Moravek (Brea, CA, USA). Stock solutions of the TB drugs were made in dimethyl sulfoxide (DMSO) (rifampin and linezolid) or Milli-Q water (isoniazid, pyrazinamide, ethambutol, amikacin, and moxifloxacin hydrochloride). Stock solutions of metformin were made in Milli-Q water. Hanks' balanced salt solution (HBSS), GlutaMAX high-glucose Dulbecco's modified Eagle medium (DMEM), and fetal calf serum (FCS) were provided by Life Technologies (Bleiswijk, The Netherlands). Bovine serum albumin (BSA) was obtained from Roche Diagnostics GmbH (Mannheim, Germany). Sodium butyrate and HEPES both were purchased from Sigma-Aldrich (Zwijndrecht, the Netherlands). BD BioCoat poly-D-lysine-coated 24-well tissue culture plates were ordered from VWR (Leuven, Belgium). High-performance liquid chromatography (HPLC)-grade methanol was purchased from Lab Scan (Dublin, Ireland) and NaOH from Merck (Darmstadt, Germany). Protein concentrations were determined with an assay kit from Bio-Rad Laboratories (Veenendaal, The Netherlands).
Cell line maintenance and transduction. Human embryonic kidney 293 (HEK293) cells were maintained at 37°C with 5% CO 2 in DMEM containing 10% FCS. After growing cells to 70% confluence, cells were diluted 4ϫ to 5ϫ in the DMEM culture medium and seeded in poly-Dlysine-coated 24-well plates in a volume of 375 l per well. (EYFP) . To produce the recombinant baculovirus, genes of interest were cloned downstream of a cytomegalovirus (CMV) promoter into a baculovirus for protein expression in mammalian cells as described previously (16) . Of note, such an overexpression setup does not allow for the assessment of DDIs caused by induction of transporter proteins. To enhance protein expression, 195 l DMEM (10% FCS) containing 6 mM sodium butyrate was added to each well (2 mM final concentration). Uptake experiments with the cell monolayers were performed 2 or 3 days postransduction.
Inhibition of OCT1-, OCT2-, OCT3-, MATE1-, and MATE2K-mediated metformin uptake by TB drugs. On the day of the transport experiment, the culture medium was removed and cells were first washed in order to equilibrate them to serum-free conditions with 400 l buffer (HBSS plus 10 mM HEPES, pH 7.4), prewarmed to 37°C. Uptake was initiated by replacing this solution with 150 l of fresh transport buffer (HBSS-HEPES, pH 7.4 [pH 8.5 in case of MATE2K], kept at 37°C) supplemented with the TB drug(s) of interest and incubated at 37°C for either 5 min (MATE1 and MATE2K) or 10 min (OCTs). Similar to the OCTs, MATE1 and MATE2K activity levels were measured in the uptake direction, even though in the kidney and liver the MATEs export organic cations into the urine and bile, respectively. MATE2K import was further stimulated by increasing the proton gradient (alkaline transport buffer, pH 8.5) (17) .
To enable screening for metformin uptake inhibition, the transport buffer contained 6 M [ 14 C]metformin (equaling plasma maximum concentrations [C max ] of 10 M [18] ) and 200 M TB drug (rifampin, isoniazid, pyrazinamide, ethambutol, moxifloxacin hydrochloride, amikacin, or linezolid). TB drugs were selected to represent the range of available first-and second-line TB drugs according to the WHO (19), including rifampin, isoniazid, pyrazinamide, and ethambutol (group I first-line oral agents); amikacin (group II injectable aminoglycosides); moxifloxacin (group III fluoroquinolones); and linezolid (group V TB drugs with unclear efficacy). Screening occurred at 200 M TB drug, because this was assumed to be a maximum physiologically relevant concentration. Following the results of these experiments, the concentrationdependent inhibition of moxifloxacin on MATE1-and MATE2K-mediated metformin transport was determined. Cells were coincubated with increasing concentrations of moxifloxacin (0.1, 0.3, 3, 30, 100, 300, and 1,000 M) to enable determination of the 50% inhibitory concentration (IC 50 ). For all experiments, compound solvents (Milli-Q or DMSO [1%]) were used as positive controls. Uptake was stopped at 5 or 10 min as indicated above by removing the transport buffer and immediately rinsing the monolayers with 400 l of ice-cold HBSS-HEPES buffer contain-
FIG 1
Schematic overview of the most important transporters involved in the absorption, hepatic uptake, and excretion of metformin (11, 15, (40) (41) (42) (43) .
The physiological significance of the transporters, depicted in gray, are still unclear (11) . PMAT is mostly responsible for the uptake of metformin from the gastrointestinal tract, being far more abundant than OCT3. OCT1 and OCT3 together mediate the uptake of metformin in the liver, which is the most important site of action of metformin. The biliary excretion of metformin from the hepatocyte via MATE1 seems negligible in humans, and OCT1 and OCT3 probably also transport their substrates from the hepatocyte back into the blood. In the kidneys, OCT2 mediates the uptake of metformin into the proximal tubular cells, and MATE1 and MATE2K are responsible for the excretion of metformin into the urine. In the present study, we did not assess any interaction mediated via PMAT.
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ing 0.5% BSA (pH 7.4), followed by washing with 400 l of ice-cold HBSS-HEPES buffer (pH 7.4).
To measure intracellular [ 14 C]metformin concentrations, cells were solubilized in 200 l of 1 M NaOH and the radioactivity was determined in aliquots of the lysate after adding 4 ml Opti-fluor scintillation fluid (PerkinElmer, Waltham, MA, USA). Radioactivity was measured using a Packard Tri-Carb liquid scintillation counter (Ramsey, MN, USA). In all experiments, transporter-dependent uptake was calculated by subtracting the background (vector control cells containing EYFP) from the corresponding values measured in the HEK transporter cells and expressed relative to the vehicle (positive) control.
Identification of OCT1, OCT2, OCT3, MATE1, and MATE2K TB drug substrates. To determine whether TB drugs are substrates of OCT1, OCT2, OCT3, MATE1, and MATE2K, the uptake of rifampin, pyrazinamide, ethambutol, amikacin, moxifloxacin, and linezolid was determined in HEK cells transiently expressing the respective transporters as well as EYFP. Intracellular isoniazid could not be quantified under current test conditions. The cells were incubated with HBSS-HEPES (HBSS-HEPES, pH 7.4; pH 8.5 in the case of MATE2K) containing 10 M (rifampin and moxifloxacin) or 100 M (isoniazid, pyrazinamide, ethambutol, amikacin, and linezolid) TB drugs at 37°C for 10 min. After the washing steps with ice-cold HBSS-HEPES, cells were solubilized in 200 l of 50% methanol-0.1% formic acid mixture.
Aliquots were analyzed using liquid chromatography-tandem mass spectrometry (LC-MS/MS), consisting of an ultraperformance liquid chromatograph (UPLC; Acquity I-class; Waters, Milford, MA, USA) coupled to a triple-quadrupole MS (TQ-S micro; Waters, Milford, MA, USA). Separation was performed with LC at 40°C using an HSS T3 analytical (E). Transport is expressed as a percentage of solvent controls and is presented as means Ϯ SEM. Inhibition greater than 70% is indicated by the gray bars. This drug (moxifloxacin) was selected to further determine concentration-dependent inhibition. Data were pooled from three independent experiments. An asterisk indicates a statistically significant difference from control by one-way ANOVA using Dunnett's post hoc test (P Ͻ 0.05). MQ, Milli-Q water. [HCOOH] in acetonitrile) at a flow rate of 0.25 ml/min using the following gradient: 0 to 4 min solvent A (100%), 4 to 6 min solvent A (10%) plus solvent B (90%), and 6 to 12 min solvent A (100%). The TQ-S micro MS detector was used to assess the transitions of five selected reactions monitoring mass pairs for the quantitative analysis of all TB drugs. TB drug concentrations were recalculated into intracellular accumulation, which was expressed as picomoles per milligram of protein per minute.
Further kinetic characterization of the proposed substrate ethambutol occurred by determining time-dependent and concentration-dependent transport. Time-dependent uptake of ethambutol (100 M) was assessed by performing transport assays at various incubation times, namely, 1, 5, 10, and 15 min. Concentration-dependent uptake was determined by performing uptake assays at a concentration range (0.03, 0.1, 0.3, 1, and 3 mM) after 1 min of incubation at 37°C. Data analysis. Data were expressed as means Ϯ standard errors of the means (SEM) from three independent experiments. In each transporter assay, the average amount of cellular protein per transporter transduction was determined as a measure for the amount of cells per well. This estimation of cell death was used to correct for the effects of each transporter transduction. Cells for protein concentration determination were solubilized in 200 l 1 M NaOH and stored at Ϫ20°C upon analysis. Protein concentrations were determined using the Bio-Rad protein assay kit with BSA as a standard. Statistically significant differences in uptake (P Ͻ 0.05) due to transport inhibition were assessed using one-way analysis of variance (ANOVA) followed by Dunnett's post hoc multiple-comparison test. Curve fitting of concentration-dependent inhibition of transport and estimation of IC 50 s were established by nonlinear regression analysis using GraphPad Prism software, version 5.03 (GraphPad Software Inc., San Diego, CA, USA). Drug-drug interaction (DDI) indices, or ratios, were calculated by dividing the maximal inhibitor concentration in plasma (unbound and total C max ) by the transporter-specific in vitro IC 50 . Based on international guidelines, a cutoff of Ͼ0.1 can be assumed to warrant further prospective in vivo investigation (21) . Substantial pharmacokinetic alterations can be expected for a DDI index of Ͼ1 (21).
One-sample t tests were performed to test if drug uptake ratios of transporter-expressing cells versus control cells were statistically greater than 1. To estimate maximum transport velocity (V max ) and the substrate concentration at which half of this speed is obtained (K m ), concentrationdependent uptake data were fitted to the Michaelis-Menten equation using GraphPad Prism.
RESULTS
Inhibition of OCT1-, OCT2-, OCT3-, MATE1-, and MATE2K-mediated metformin uptake. HEK293 cells expressing OCT1, OCT2, OCT3, MATE1, and MATE2K were used to study the inhibitory action of TB drugs on metformin transport. Figure 2 shows the results of screening for inhibition at a TB drug concentration of 200 M. First, it can be observed that metformin uptake by OCT1 and OCT3 was significantly inhibited by moxifloxacin to 52% Ϯ 9% and 39% Ϯ 9% (P Ͻ 0.05) of the control conditions, respectively ( Fig. 2A and C) . Uptake remained around 50% of that of the control, indicating that the IC 50 s of moxifloxacin were around the tested concentration of 200 M. Second, for OCT2-mediated metformin transport both inhibition and stimulation were observed, although these did not reach significant levels (Fig.  2B) . Finally, Fig. 2D and E show that metformin uptake by MATE1 and MATE2K was also significantly inhibited by moxifloxacin. This time almost complete inhibition compared to the vehicle control was obtained, namely, 12% Ϯ 1% (P Ͻ 0.001) and 16% Ϯ 2% (P Ͻ 0.01), respectively. Therefore, moxifloxacin was selected to determine concentration-dependent inhibition of the MATEs. Figure 3A and B show these IC 50 curves for inhibition of metformin uptake by MATE1 and MATE2K, corresponding to IC 50 s of 12 M (95% confidence intervals [CI], 5.1 to 29 M) and 7.6 M moxifloxacin (95% CI, 0.2 to 242 M) ( Table 1) .
Identification of OCT1, OCT2, OCT3, MATE1, and MATE2K substrates. HEK293 cells expressing OCT1, OCT2, OCT3, MATE1, and MATE2K were used to determine whether TB drugs are substrates of these transporters. Figure 4A to E shows the results of screening for the uptake of TB drugs. No differences between background uptake (cells expressing EYFP) and uptake by transporter-expressing cells were observed for rifampin, pyrazin- amide, moxifloxacin, and linezolid. Amikacin transport ratios (means Ϯ SEM) for OCT3 and MATE2K relative to the control were 2.5ϫ Ϯ 1.5ϫ and 2.6ϫ Ϯ 0.5ϫ, respectively, but ratios were not statistically significant (P ϭ 0.4 and P ϭ 0.07, respectively). In short, under current test conditions we could not identify rifampin, pyrazinamide, moxifloxacin, amikacin, or linezolid as transporter substrates. In contrast, ethambutol displayed increased uptake by all transporter-expressing cells. Transport ratios amounted to 3.0ϫ Ϯ 0.4ϫ for OCT1 (P Ͻ 0.05), 3.3ϫ Ϯ 0.5ϫ for OCT2 (P ϭ 0.05), 2.4ϫ Ϯ 0.09ϫ for OCT3 (P Ͻ 0.01), 3.5ϫ Ϯ 0.8ϫ for MATE1 (P ϭ 0.09), and 1.6ϫ Ϯ 0.2ϫ for MATE2K (P ϭ 0.05). Of note, we observed higher ethambutol uptake in control cells exposed to the transport buffer at pH 8.5 (Fig. 4E) , explaining the smaller transport ratio for MATE2K. The contribution of endogenously expressed transporters may be enhanced under these conditions.
After testing an incubation time range (1, 5, 10, and 15 min), it became evident that ethambutol (100 M) uptake occurred linearly only for a very short time frame, namely, from 0 until Ͻ1 min for OCT1 and OCT2 and from 0 to approximately 1 min for 
FIG 4 Uptake of TB drugs into HEK293 cells overexpressing OCT1 (A), OCT2 (B), OCT3 (C), MATE1 (D), and MATE2K (E) relative to uptake in the control
cell line expressing EYFP. The uptake of TB drugs (10 M rifampin and moxifloxacin or 100 M isoniazid, pyrazinamide, ethambutol, amikacin, and linezolid) was assessed. Transport is expressed as pmol/mg/min and presented as means Ϯ SEM. Data were pooled from three or four independent experiments. In panels B and E, uptake of linezolid could only be performed in duplicate due to measurements being below the limit of detection.
OCT3, MATE1, and MATE2K (see the supplemental material).
This information is important when deriving Michaelis-Menten curves and equations, as accurate concentration dependency can only be established within the linear phase of transport and not under saturated transport conditions. Nonetheless, all K m -V max curves were performed with a 1-min incubation time, because it was technically not possible to perform transport assays in less than 1 min. Thus, we cannot exclude that K m values for OCT1 and OCT2 were obtained under saturated transport conditions and therefore are less reliable. Figure 5A to E demonstrates the MichaelisMenten curves of ethambutol for OCT1, OCT2, OCT3, MATE1, and MATE2K, respectively. The affinity of ethambutol, as quantified by K m , amounted to 686 M (95% CI, 0 to 1,521 M) for OCT1, 314 M (95% CI, 0 to 646 M) for OCT2, 1,356 M (95% CI, 0 to 3,584 M) for OCT3, 2,164 M (95% CI, 0 to 4,838 M) for MATE1, and 819 M (95% CI, 0 to 2,660 M) for MATE2K. To enable the determination of reliable affinity constants, substrate concentrations in the Michaelis-Menten plot should increase until 3 to 5 times the K m value, which was not the case for OCT3 and MATE1 (Fig. 5) . However, testing at higher ethambutol concentrations (Ͼ3 mM) was deemed physiologically irrelevant.
Inhibition of OCT1-, OCT2-, OCT3-, MATE1-, and MATE2K-mediated ethambutol uptake. Figure 6 shows the results of screening for the inhibitory effect of metformin and moxifloxacin (200 M) on ethambutol uptake by OCT1 (A), OCT2 (B), OCT3 (C), MATE1 (D), and MATE2K (E). Only metformin inhibited MATE2K-mediated ethambutol uptake significantly, but activity was not reduced to Ͻ30% of the control. Moxifloxacin significantly inhibited ethambutol transport by OCT1, OCT3, and MATE1. In the case of OCT3 and MATE1, inhibition was reduced Ͼ70%, namely, 25% Ϯ 5% (P Ͻ 0.01) and 10% Ϯ 1% (P Ͻ 0.05) of the control, respectively (Fig. 6C and D) . Moxifloxacin concentration-dependent inhibition was further determined for OCT3 and MATE1 (Fig. 7A and B) . IC 50 s corresponded to 154 M (95% CI, 60 to 393 M) for OCT3 and 12 M (95% CI, 3.4 to 43 M) for MATE1 (Table 1) .
DISCUSSION
This study assessed the in vitro inhibitory effects of TB drugs (rifampin, isoniazid, pyrazinamide, ethambutol, amikacin, moxifloxacin, and linezolid) on the transport of metformin by OCT1, OCT2, OCT3, MATE1, and MATE2K. We found that moxi- , respectively) but is not a substrate for these transporters itself. We did identify ethambutol as a substrate of OCT1, OCT2, OCT3, MATE1, and MATE2K, even though it did not have a strong (competitive) inhibitory effect on metformin transport. Finally, we demonstrated that MATE1-mediated ethambutol uptake was also inhibited strongly (DDI index of Ͼ0.1) by moxifloxacin (12 M [95% CI, 3.4 to 43 M]) but not by metformin. TB drugs other than moxifloxacin did not inhibit OCT-and MATE-mediated transport of metformin, and ethambutol was the only substrate for these transporters among the TB drugs investigated. This study identified moxifloxacin as a potent MATE1 (metformin and ethambutol uptake) and MATE2K (metformin uptake) inhibitor. The relatively weaker inhibition of OCT1 and OCT3 (metformin and ethambutol uptake) do not exceed the proposed DDI index threshold of 0.1 (Table 1 ) but may still be relevant at the site of the intestinal lumen, where drug exposure is expected to be higher than that in plasma. However, the contributions of OCTs to intestinal uptake remain rather unclear, as they are far less abundant than the plasma membrane monoamine transporter (PMAT) (Fig. 1 (D), and MATE2K (E). Transport is expressed as a percentage of solvent controls and is presented as means Ϯ SEM. Inhibition greater than 70% is indicated by the gray bars. This drug (moxifloxacin) was selected to further determine concentration-dependent inhibition. Data were pooled from three independent experiments. An asterisk indicates a statistically significant difference from the control by one-way ANOVA using Dunnett's post hoc test (P Ͻ 0.05). MQ, Milli-Q water.
of 5 and 1 M, respectively (22) . From the literature we know that inhibitors of OCT and MATE can have a clinically relevant impact on the pharmacokinetics of concomitantly administered organic cations through reduction in their renal clearance (14, 15, 23) . Known inhibitors are cimetidine for OCT2 (IC 50 of 110 M [24] ) and MATE1/MATE2K (K i of 7 and 1 M, respectively [25] ) as well as pyrimethamine for OCT2 (K i of 10 M [15] ) and MATE1/ MATE2K (K i of 93 and 59 nM, respectively [15] ). Both inhibitors also increased plasma concentrations of metformin, even though the IC 50 of cimetidine for the basolaterally located OCT2 does not seem clinically relevant (DDI index of 0.07 [26] ). In contrast to cimetidine, the selective MATE2K inhibitor nizatidine did not significantly reduce renal clearance of metformin in 12 healthy volunteers, but it did increase the apparent volume of distribution, half-life, and hypoglycemic activity of metformin, possibly indicating increased metformin accumulation and subsequent glucose handling in renal cells, with continued renal filtration as well as secretory clearance via MATE1 (22) .
When comparing cimetidine IC 50 s for MATE1 and MATE2K (DDI index of 1.1 and 7.9, respectively) with those of moxifloxacin in this study (DDI index of 1.3 and 2.0, respectively), the indices can be considered relatively similar, and therefore a clinically significant interaction may be anticipated for moxifloxacin coadministered with MATE substrates such as metformin. DDI indices for MATEs may even be underestimated, as these are based on (unbound) plasma concentrations, while MATE exporters are inhibited from inside the cell. Because moxifloxacin has a high volume of distribution (ϳ3 liters/kg [27] ), is lipophilic, and has low protein binding (50%), it is likely that intracellular accumulation occurs beyond the central compartment.
Reported findings for moxifloxacin may also have implications for the coadministration of levofloxacin (another group III fluoroquinolone TB drug) with cations, such as metformin. Previously, levofloxacin was demonstrated to inhibit human MATE1 (IC 50 of 38 M) and human MATE2K (IC 50 of 82 M) (28). IC 50 s were reported for the model MATE substrate tetraethylammonium (TEA), but effects may be different for other substrates. Further research should assess the inhibitory potential of levofloxacin on transport of metformin and ethambutol to draw more firm conclusions with respect to its DDI potential.
Although metformin is known to have a very favorable safety profile, including a minimal risk of hypoglycemia, decreased elimination of metformin might pose a higher risk for adverse effects, such as lactic acidosis (11, 29) . However, lactic acidosis occurs only very rarely. On the other hand, MATE inhibition could also strengthen the glucose-lowering effect of metformin, either via the liver due to increased plasma and hepatocyte exposure or via the kidneys due to local metformin accumulation. Kidneys are known to have a minor but significant role in glucose uptake, gluconeogenesis, and glucose utilization (30, 31) . Overall, with current in vitro data it is hard to predict the effect of moxifloxacin-induced inhibition of renal excretion on accumulation in renal tubular cells, increased plasma concentrations, and pharmacodynamic endpoints. These processes should also be considered when building and refining a physiologically based pharmacokinetic (PBPK) model to predict pharmacokinetic DDIs in the kidneys based on in vitro data.
To our knowledge, our study is the first to demonstrate that ethambutol is a substrate of cation transporters, such as the OCTs and the MATEs. This finding provides a mechanistic basis for DDI predictions concerning ethambutol. For example, available data suggest that the combination of ethambutol with inhibitors of OCTs and MATEs, such as moxifloxacin, have pharmacokinetic implications. Ethambutol is part of the first-line TB treatment regimen together with isoniazid, rifampin, and pyrazinamide, as recommended by the World Health Organization (WHO) (19) , even though it is considered to have limited bactericidal activity. Similar to metformin, ethambutol has a positive charge at physiologic pH and has low lipophilicity with a negative logP of Ϫ0.14 (32). Renal elimination is its major clearance mechanism, with approximately 50 to 70% of oral doses and 70 to 84% of intravenous doses being recovered unchanged in the urine of subjects with normal renal function (33, 34) . The renal clearance rate (ϳ417 ml/min) indicates that both active net tubular secretion and glomerular filtration (120 ml/min) are involved (35) . We previously did not know to what degree transporters are involved in the disposition of ethambutol. Only the study by Pan et al. had demonstrated an inhibitory potential of ethambutol on OCTs, but IC 50 s were in the higher micromolar range (36) .
There are no interaction studies available that have assessed the effect of moxifloxacin as an inhibitor on ethambutol pharmacokinetics. Current efforts to incorporate moxifloxacin in the firstline TB treatment regimen mainly focus on replacing ethambutol (37, 38) . For future regimens containing both ethambutol and moxifloxacin, it could be of interest to perform an in vivo interaction study. Such studies are indispensable to assess the contribu- tion of inhibition of single or multiple transporters expressed in various organs throughout the human body and to evaluate the clinical relevance of an observed pharmacokinetic interaction. An in vivo interaction study is not warranted for the interaction between metformin and ethambutol (Table 1) . SLC transporters may be less likely to be saturated by competition of two substrates, which is supported by the high K m values of both metformin and ethambutol (high micromolar and millimolar range) (39) and the high IC 50 s on the function of OCTs in the study by Pan et al. (36) .
In summary, we found moxifloxacin to be a potent inhibitor of MATE1-and MATE2K-mediated metformin transport and identified ethambutol as a substrate of OCT1, OCT2, OCT3, MATE1, and MATE2K. Furthermore, we demonstrated that MATE1-mediated ethambutol uptake was also inhibited by moxifloxacin but not by metformin. According to international guidelines, our results warrant further in vivo interaction studies. The data could also serve as valuable input for PBPK modeling to predict intracellular and plasma drug concentrations of metformin and ethambutol and simulate clinical DDIs with these drugs.
